Sinotherapeutics Inc. (SHA:688247)

Market Cap	4.75B
Revenue (ttm)	512.69M
Net Income (ttm)	128.23M
Shares Out	449.00M
EPS (ttm)	0.28
PE Ratio	37.75
Forward PE	n/a
Dividend	0.05 (0.48%)
Ex-Dividend Date	Oct 25, 2024

Volume	2,060,300
Average Volume	4,322,462
Open	10.37
Previous Close	10.37
Day's Range	10.24 - 10.43
52-Week Range	7.27 - 14.00
Beta	0.10
RSI	51.05
Earnings Date	Apr 30, 2025

About Sinotherapeutics

Sinotherapeutics Inc., a specialty pharmaceutical company, develops generic and formulation products in China. It offers posaconazole delayed-release tablets, ursodeoxycholic acid capsules, bupropion hydrochloride extended-release tablets, paroxetine extended-release tablets, sevelamer carbonate tablets, and propafenone hydrochloride extended-release capsules. The company provides CRO/CDMO services including pre-formulation study, formulation and process development, clinical sample manufacturing, NDA registration batch manufacturing, quality s...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2012
• Employees: 260
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688247

Financial Performance

In 2024, Sinotherapeutics's revenue was 512.69 million, an increase of 70.97% compared to the previous year's 299.87 million. Earnings were 128.23 million, an increase of 109.97%.